Targets for COVID-19 vaccine identified
Scientists have identified regions of the SARS-CoV-2 virus that causes COVID-19 to target with a vaccine, by harnessing tools used for the development ofcancer immunotherapies.
https://www.ksgindia.com/study-material/news-for-aspirants/23915-targets-for-covid-19-vaccine-identified.html
#covid19 #vaccine #cancer

Govt amended the CSR norms
The government has amended the corporate social responsibility rules under the companies law that is likely to help boost funding for developing new vaccines, drugs and medical devices related to the coronavirus pandemic.
Read More: https://www.ksgindia.com/study-material/news-for-aspirants/25188-govt-amended-the-csr-norms.html
#Govtamended #CSRnorms #vaccine #COVID19 #UPSCOnlineClasses #OnlineClassses #IASOnlineclasses

Watch KSG Explainer: India's indigenous vaccine Covaxin approved for Emergency use by WHO #UPSC #IAS
https://www.youtube.com/watch?v=a5qrDtSFiNQ

Watch: Scientists identify antibodies that can block Omicron variant #antibodies #omicronvariant #covid
https://www.youtube.com/watch?v=qma5v1Wa2nc

KSG Podcast - The journey of Mosquirix | Short Crisp Concise and Exam Oriented Edited Editorial
https://www.youtube.com/watch?v=eyK4geL4i24&list=PLCUwtp5IghZmJBi1h7xiAhsORKmmumVsR&index=2
#UPSCOnlineClasses #OnlineClassses #IASOnlineclasses

KSG Podcast - Climate and the Quad | best daily editorial analysis for upsc
https://www.youtube.com/watch?v=L0sdo0b59Vw&t=1s
#UPSCOnlineClasses #OnlineClassses #IASOnlineclasses

KSG Podcast - The journey of Mosquirix | Short Crisp Concise and Exam Oriented Edited Editorial
https://www.youtube.com/watch?v=eyK4geL4i24&list=PLCUwtp5IghZmJBi1h7xiAhsORKmmumVsR&index=52
#UPSCOnlineClasses #OnlineClassses #IASOnlineclasses

Today's Headlines - 23 August 2023
Maternal vaccine to prevent RSV in infants
GS Paper - 3 (Health and Diseases)

The United States became the first country to approve a vaccine for pregnant women that prevents severe disease caused by Respiratory Syncytial Virus (RSV) in their babies.

More about the Vaccine

The Pfizer shot, which was already approved for use in older adults, has now been greenlighted for use as a single injection from 32 through 36 weeks of pregnancy, to protect infants from birth through six months.
It is the latest in a succession of medicines recently approved against the common microbe, which causes tens of thousands of hospitalizations among infants and the elderly in the United States every year.
Researchers have targeted an RSV vaccine since the 1960s, but the spates of shots that are emerging now were made possible thanks to a scientific breakthrough a decade ago.
RSV is a common cause of illness in children and infants are among those at highest risk for severe disease, which can lead to hospitalization.
This approval provides an option for healthcare providers and pregnant individuals to protect infants from this potentially life-threatening disease.
The approval follows a clinical trial involving some 7,000 pregnant women, which showed Pfizer's vaccine, called Abrysvo, reduced severe disease caused by RSV by 82 percent in babies from 0-3 months, and 69 percent from 0-6 months.
Abrysvo was previously approved by the FDA for adults aged 60 and over, as was another vaccine by drugmaker GSK, called Arexvy.
While RSV most often causes mild, cold-like symptoms in infants and young children, it can also lead to more serious outcomes such as pneumonia and bronchiolitis.

#upsc #news #headline #maternal #vaccine #RSV #healthanddiseases #country #pregnantwomen #severedisease #respiratory #syncytical #virus #vaccine #protectinfacts #commonmicrbe #spatesofshots #illness #healthcare #disease #succession #scientific #hospitalizations #medicines #women #abrysvo #FDA #Arexvy #symptoms #pneumonia #bronchiolitis